SCHEMBL3767958

SCHEMBL3767958

O=C(CN1CCN(c2ccc(-c3cccc(OC(F)(F)F)c3)cc2)CC1)N1CCN(C2CCC2)CC1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A7 Q99884 1/20 0.47
MCHR1 Q99705 3/20 0.46
ALDH1A1 P00352 4/20 0.44
MAPT P10636 4/20 0.44
PIM1 P11309 1/20 0.44
RORC P51449 1/20 0.43
ENPP2 Q13822 2/20 0.42
KDM4E B2RXH2 2/20 0.42
CHRM4 P08173 2/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
HTT P42858 1/20 0.42
MAPK1 P28482 1/20 0.42
MEN1 O00255 1/20 0.41
TSHR P16473 1/20 0.41
KMT2A Q03164 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3767785 0.91 EPHX2 (0.48) ALDH1A1MAPTKDM4ECHRM4LMNA
SCHEMBL3773249 0.88 KDM2B (0.51) ALDH1A1MAPTKDM4ELMNAGAA
SCHEMBL3773820 0.86 ACHE (0.47) ALDH1A1MAPTKDM4ELMNAGAA
SCHEMBL3762984 0.86 ALDH1A1 (0.45) ALDH1A1MAPTKDM4ELMNAGAA
SCHEMBL3773996 0.86 KDM2B (0.51) ALDH1A1MAPTKDM4ELMNAGAA
SCHEMBL3777299 0.85 MAPK1 (0.55) ALDH1A1MAPTKDM4ELMNAHTT
SCHEMBL13005908 0.84 ALDH1A1 (0.44) ALDH1A1MAPTKDM4ELMNAMAPK1
SCHEMBL5555542 0.84 PANK3 (0.43) SLC6A7MCHR1ALDH1A1MAPTPIM1
SCHEMBL3762866 0.84 ALDH1A1 (0.64) ALDH1A1MAPTKDM4ELMNAGAA
SCHEMBL3767567 0.83 ALDH1A1 (0.47) ALDH1A1MAPTKDM4ELMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 SLC6A7 1197/4885MCHR1 239/4885ALDH1A1 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.